Shares in New York headquartered Immune Pharmaceuticals Inc. ended Friday's session 1.29% lower at $0.16, with a total trading volume of 2.22 million shares. The stock is trading 30.80% below its 50-day moving average. Shares of the Company, which develops and commercializes novel targeted therapeutics in the immuno-inflammation and immuno-oncology areas, have a Relative Strength Index (RSI) of 35.31.
On November 17th, 2016, Immune Pharmaceuticals announced that it has secured up to $11 million in new financing from a single family office that is an existing investor. The financing includes the sale of a $1 million convertible note and up to $10 million in future equity sales at prevailing market prices in increments of at least $1 million per month. Immune continues to accrue patients in two phase 2 clinical trials for bertilimumab, a first-in-class monoclonal antibody targeting eotaxin-1: an open label 10 patient trial in the treatment of bullous pemphigoid, an orphan auto-immune dermatological condition, and a double-blind, placebo-controlled, 42 patient trials in moderate-to-severe ulcerative colitis, a gastrointestinal inflammatory condition. IMNP complete research report is just a click away and free at:
Paris, France headquartered Sanofi's shares rose 1.01%, closing the day at $39.84, with a total trading volume of 710,745 shares. The stock has advanced 7.50% in the last month and 2.71% in the previous three months. The Company's shares are trading 2.32% above their 50-day moving average and 0.40% above their 200-day moving average. Additionally, shares of Sanofi, which researches, develops, manufactures, and markets various therapeutic solutions, have an RSI of 50.02.
On November 07th, 2016, research firm Goldman initiated a 'Neutral' rating on the Company's stock.
On November 17th, 2016 - Sanofi and Regeneron Pharmaceuticals announced that the ongoing Praluent® (alirocumab) ODYSSEY OUTCOMES trial will continue as planned, based on the recommendation of an independent Data Monitoring Committee (DMC) after it completed a second pre-specified interim analysis. The DMC will continue to monitor the ongoing safety and efficacy of Praluent as planned. The Phase 3, multi-center, randomized, double-blind, placebo-controlled ODYSSEY OUTCOMES trial involves more than 18,000 patients from 57 countries. The complimentary report on SNY can be downloaded at:
Last Friday, shares in Xianyang, the People's Republic of China headquartered Biostar Pharmaceuticals Inc. plummeted 10.73%, closing the session at $3.41. The stock recorded a trading volume of 695,804 shares. The Company's shares have advanced 38.06% over the previous three months and 21.79% on an YTD basis. The stock is trading 16.88% above its 200-day moving average. Furthermore, shares of Biostar Pharma, which develops, manufactures, and markets over-the-counter and prescription pharmaceutical products for various diseases and conditions in the People's Republic of China, have an RSI of 50.71.
On November 21st, 2016, Biostar Pharmaceuticals reported net sales of $0.6 million for Q3 2016, a decrease of approximately $3.6 million, or 84.7% compared to Q3 2015. The company's gross profit decreased by approximately $0.5 million, or 62.3% for Q3 2016 compared to Q3 2015. Biostar Pharmaceuticals reported net loss of $1.6 million for Q3 2016 compared to a net loss of $1.2 million for Q3 2015. Sign up for your complimentary research report on BSPM at:
Dublin, Ireland headquartered Shire PLC's stock finished the session 0.84% higher at $175.34, with a total trading volume of 908,697 shares. Shares of the Company, which together with its subsidiaries, researches, develops, licenses, manufactures, markets, distributes, and sells pharmaceutical products, are trading below their 200-day moving average by 3.76%. The stock has an RSI of 43.53.
On November 22nd, 2016, Shire announced that it will expand its operations in Cambridge, Massachusetts, establishing a rare disease innovation hub and increasing its footprint in the heart of Kendall Square. Shire and BioMed Realty have signed a lease for a 343,000-square-foot building at 500 Kendall Street. Shire's lease begins in Q3 2018, with occupancy anticipated for Q1 2019. With the adjacent space it currently occupies at 650 Kendall St., Shire will create a cross-disciplinary Kendall Square campus, with teams spanning research, clinical development, medical affairs, business development, and other related functions. Get free access to your research report on SHPG at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA